

Floor J Backes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6809915/publications.pdf>

Version: 2024-02-01

93
papers

3,770
citations

126708

33
h-index

138251

58
g-index

95
all docs

95
docs citations

95
times ranked

4771
citing authors

#	ARTICLE	IF	CITATIONS
1	Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. American Journal of Obstetrics and Gynecology, 2011, 204, 466-478.	0.7	343
2	Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal of Clinical Oncology, 2018, 36, 2044-2051.	0.8	313
3	Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecologic Oncology, 2017, 146, 405-415.	0.6	298
4	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research, 2018, 24, 777-783.	3.2	171
5	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 4301-4308.	0.8	163
6	Randomized Phase II Trial of Carboplatin+Paclitaxel Compared with Carboplatin+Paclitaxel+Trastuzumab in Advanced (Stage III+IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research, 2020, 26, 3928-3935.	3.2	154
7	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2016, 34, 3062-3068.	0.8	141
8	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecologic Oncology, 2015, 136, 246-253.	0.6	104
9	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecologic Oncology, 2018, 148, 174-180.	0.6	83
10	Epigenetic silencing of <i>MLH1</i> in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecologic Oncology, 2017, 146, 588-595.	0.6	77
11	Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecologic Oncology, 2016, 141, 312-317.	0.6	75
12	Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology, 2009, 114, 486-490.	0.6	68
13	Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecologic Oncology, 2012, 125, 546-551.	0.6	64
14	Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients. Obstetrics and Gynecology, 2009, 114, 530-536.	1.2	62
15	Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. American Journal of Obstetrics and Gynecology, 2020, 222, 60.e1-60.e7.	0.7	58
16	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. Gynecologic Oncology, 2016, 142, 139-143.	0.6	57
17	Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecologic Oncology, 2008, 111, 461-466.	0.6	52
18	Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecologic Oncology, 2017, 145, 519-525.	0.6	52

#	ARTICLE	IF	CITATIONS
19	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Uterine Serous Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S83-S89.	1.2	51
20	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. <i>Gynecologic Oncology</i> , 2021, 160, 817-826.	0.6	51
21	Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). <i>Gynecologic Oncology</i> , 2019, 153, 496-499.	0.6	50
22	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 269-272.	0.6	49
23	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
24	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. <i>Gynecologic Oncology</i> , 2017, 147, 110-114.	0.6	46
25	Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. <i>Gynecologic Oncology</i> , 2013, 128, 309-315.	0.6	44
26	The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion. <i>American Journal of Surgical Pathology</i> , 2017, 41, 49-55.	2.1	44
27	Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 109.e1-109.e11.	0.7	43
28	ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 ^{+/+} Ovarian Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 199-210.	1.9	43
29	Endometrial cancer patients and compliance with genetic counseling: Room for improvement. <i>Gynecologic Oncology</i> , 2011, 123, 532-536.	0.6	40
30	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. <i>Genetics in Medicine</i> , 2012, 14, 670-680.	1.1	40
31	Robotic Trocar Site Small Bowel Evisceration After Gynecologic Cancer Surgery. <i>Obstetrics and Gynecology</i> , 2008, 112, 462-464.	1.2	39
32	Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 59-68.	1.2	38
33	Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. <i>Gynecologic Oncology</i> , 2014, 133, 43-47.	0.6	35
34	Mismatch repair deficiency identifies patients with high-intermediate risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. <i>Cancer</i> , 2019, 125, 398-405.	2.0	35
35	Lynch Syndrome. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 199-214.	0.6	31
36	Noncatalytic <i>PTEN</i> missense mutation predisposes to organ-selective cancer development in vivo. <i>Genes and Development</i> , 2015, 29, 1707-1720.	2.7	29

#	ARTICLE	IF	CITATIONS
37	Neuroendocrine carcinoma of the uterine cervix: The role of multimodality therapy in early-stage disease. <i>Gynecologic Oncology</i> , 2013, 129, 135-139.	0.6	28
38	The Impact of Body Weight on Ovarian Cancer Outcomes. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1601-1605.	1.2	27
39	Complications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: Time to change back?. <i>Gynecologic Oncology</i> , 2013, 128, 60-64.	0.6	27
40	Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. <i>Gynecologic Oncology</i> , 2019, 152, 316-321.	0.6	27
41	Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?. <i>Gynecologic Oncology</i> , 2014, 135, 95-99.	0.6	25
42	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	0.6	24
43	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233.		24
44	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2017, 146, 247-253.	0.6	23
45	Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. <i>Gynecologic Oncology</i> , 2014, 135, 90-94.	0.6	22
46	The role of sentinel lymph nodes in endometrial and cervical cancer. <i>Journal of Surgical Oncology</i> , 2015, 112, 753-760.	0.8	21
47	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. <i>Gynecologic Oncology</i> , 2017, 144, 96-100.	0.6	21
48	Reducing readmissions after robotic surgical management of endometrial cancer:A potential for improved quality care. <i>Gynecologic Oncology</i> , 2013, 131, 508-511.	0.6	20
49	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. <i>Gynecologic Oncology</i> , 2021, 160, 827-834.	0.6	20
50	Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1271-1276.	1.2	18
51	A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 429-434.	0.3	17
52	Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer—A Phase 1 Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 682-686.	1.2	16
53	Intraoperative radiation therapy (IORT) for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2015, 138, 449-456.	0.6	16
54	Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1331-1336.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 438-445.	1.1	15
56	Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. <i>Familial Cancer</i> , 2009, 8, 483-487.	0.9	14
57	The Use of Transvaginal Ultrasound in Type II Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 858-862.	1.2	14
58	Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2019, 152, 554-559.	0.6	14
59	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> , 2017, 123, 985-993.	2.0	13
60	Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?. <i>Gynecologic Oncology</i> , 2017, 144, 290-293.	0.6	13
61	The effect of preoperative nutritional status on postoperative complications and overall survival in patients undergoing pelvic exenteration: A multi-disciplinary, multi-institutional cohort study. <i>American Journal of Surgery</i> , 2019, 218, 275-280.	0.9	12
62	Synuclein β in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. <i>Cancer</i> , 2017, 123, 1144-1155.	2.0	11
63	Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 255-258.	0.6	10
64	Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?. <i>Gynecologic Oncology</i> , 2012, 127, 362-366.	0.6	9
65	Hysterectomy for the Treatment of Gynecologic Malignancy. <i>Clinical Obstetrics and Gynecology</i> , 2014, 57, 115-127.	0.6	9
66	Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. <i>Gynecologic Oncology</i> , 2015, 138, 689-693.	0.6	9
67	Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 614-619.	0.6	9
68	Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI. <i>Gynecologic Oncology</i> , 2016, 140, 405-408.	0.6	9
69	Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival. <i>Gynecologic Oncology</i> , 2018, 150, 38-43.	0.6	9
70	Training the Next Generation of Robotic Surgeons Using Guided Mentorship: A Randomized Controlled Trial. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 1075-1079.	0.3	8
71	Robotic radical hysterectomy and pelvic lymphadenectomy for uterine rhabdomyosarcoma. <i>Journal of Robotic Surgery</i> , 2008, 2, 197-200.	1.0	7
72	Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 833-838.	1.2	7

#	ARTICLE	IF	CITATIONS
73	Salpingectomy, why not?. American Journal of Obstetrics and Gynecology, 2014, 210, 385-386.	0.7	7
74	Predicting Inpatient Stay Lasting 2 Midnights or Longer After Robotic Surgery for Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2015, 22, 583-589.	0.3	7
75	Dermatofibrosarcoma protuberans: A rare and devastating tumor of the vulva. Gynecologic Oncology Reports, 2019, 28, 9-11.	0.3	7
76	Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. Neoplasia, 2020, 22, 484-496.	2.3	7
77	Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story?. Oncologist, 2021, 26, 1044-1051.	1.9	7
78	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecologic Oncology, 2021, 162, 619-625.	0.6	7
79	A Novel Estrogen Receptor β Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition. Cancers, 2022, 14, 2311.	1.7	7
80	Management of a rapidly enlarging new adnexal mass: a rare case of desmoplastic small round cell tumor of the ovary arising in pregnancy. Gynecologic Oncology Reports, 2016, 17, 23-25.	0.3	6
81	Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation. International Journal of Gynecological Cancer, 2016, 26, 35-42.	1.2	6
82	Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 396-401.	0.6	6
83	Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. International Journal of Cancer, 2018, 143, 2955-2961.	2.3	6
84	Imaging across the Life Span: Innovations in Imaging and Therapy for Gynecologic Cancer. Radiographics, 2014, 34, 1062-1081.	1.4	5
85	Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers. Current Oncology Reports, 2021, 23, 75.	1.8	5
86	Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy. Gynecologic Oncology, 2022, 164, 628-638.	0.6	4
87	Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. Gynecologic Oncology, 2017, 144, 451-455.	0.6	2
88	Overview of epithelial ovarian cancer and updates in management strategies. Expert Review of Obstetrics and Gynecology, 2009, 4, 383-399.	0.4	1
89	Role of Minimally Invasive Surgery in Gynecologic Malignancies. , 2018, , 560-578.e11.		1
90	Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy. Gynecologic Oncology Reports, 2021, 38, 100872.	0.3	1

#	ARTICLE	IF	CITATIONS
91	Corrigendum to "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer" [Gynecologic Oncology 111 (2008) 461-466]. Gynecologic Oncology, 2010, 119, 603.	0.6	0
92	Response to Dr. Carter's letter to the editor regarding "Short and long term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging" Gynecologic Oncology, 2013, 128, 148.	0.6	0
93	Late side effects of robotic surgery. Gynecologic Oncology, 2016, 140, 375-376.	0.6	0